Microchips Biotech has developed an implantable technology that releases drugs in the body in a controlled manner. Though the technology was developed a decade ago, it is only now that it is introduced for use.
The company has now partnered with Teva Pharmaceutical to produce the initial product and put it through clinical trials.
AdvertisementThe implantable chip has tiny reservoirs, each containing one dose of a particular medication. A metal membrane caps top of these reservoirs, which can be moved out of the way by delivering an electric current.
Depending on the applied current each reservoir can be individually activated to open up, allowing for administration at the exact times and even withámultiple medications.
The company's microchips have already gone through a successful clinical trial on patients with osteoporosis, delivering teriparatide directly without having to go through regular injections.
The study demonstrated that the programmable implant was able to deliver the drug at scheduled intervals. Drug delivery and evaluation in patients occurred over a one month period and provided proof-of-concept measures of drug release and device durability that support implantable device viability for 12 months or more.
"A microchip that continues to deliver teriparatide with this or similar consistency and efficiency over 12 to 24 months could improve bone mass, density, architecture, and strength," said study co-author Robert Neer, Founder & Director of the Massachusetts General Hospital Bone Density Center and Associate Professor of Medicine at Harvard Medical School.